Recombinant Human EPHB4 protein (rFc Tag)
种属
Human
纯度
>90 %, SDS-PAGE
标签
rFc Tag
生物活性
未测试
验证数据展示
产品信息
| 纯度 | >90 %, SDS-PAGE |
| 内毒素 | <0.1 EU/μg protein, LAL method |
| 生物活性 |
Not tested |
| 来源 | HEK293-derived Human EPHB4 protein Leu16-Ala539 (Accession# P54760) with a rabbit IgG Fc tag at the C-terminus. |
| 基因ID | 2050 |
| 蛋白编号 | P54760 |
| 预测分子量 | 83.1 kDa |
| SDS-PAGE | 83-100 kDa, reducing (R) conditions |
| 组分 | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| 复溶 | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| 储存条件 |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| 运输条件 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
背景信息
EPHB4 (Ephrin type-B receptor 4), a member of the largest family of receptor tyrosine kinases (RTK), is overexpressed in several tumor types, including prostate, breast, and bladder tumors and down-regulation of EPHB4 in tumor cell lines of these origins results in reduced cell viability, migration, and invasion. In endothelial cells, where EphB4 is normally expressed, it regulates cell migration, proliferation, and invasion. The discovery of EphB4 as an alternative Epo receptor has multiple clinical implications including opportunities for patient stratification and anti-EphB4 approaches to abrogate the stimulatory effects of Epo on tumor growth.
参考文献:
1. Xia, Guangbin et al. Cancer research vol. 65,11 (2005): 4623-32. 2. Davalos, Veronica et al. Cancer research vol. 66,18 (2006): 8943-8. 3. Erber, Ralf et al. The EMBO journal vol. 25,3 (2006): 628-41.
